Correlations of 18F-FDG PET/CT metabolic parameters and systemic immune-inflammation index with distant metastasis of small-size (T1) NSCLC

Le résumé fourni par la source

Background: F-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters and the systemic immune-inflammation index (SII) are linked to NSCLC progression, but their associations with distant metastasis in small-size NSCLC remain unclear. This study aimed to investigate these correlations to identify reliable metastatic risk factors for small-size NSCLC. Methods: F-FDG PET/CT within two weeks before tumor resection or biopsy. PET/CT metabolic parameters including standardized uptake value peak (SUVpeak), standardized uptake value maximum (SUVmax), standardized uptake value mean (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and coefficient of variation (COV) at various SUV thresholds (1.0, 1.5, 2.0, and 2.5) were assessed for primary lesions. Inflammation factors including SII were measured one day prior to surgery or biopsy. Patients were randomized into modeling (n=182) and validation (n=61) cohorts (3:1). Univariate/multivariate logistic regression analyses identified independent risk factors for metastasis correlations between metabolic parameters and serum inflammation markers were analyzed. Results: In the modeling cohort, high SUVpeak, SUVmean, SUVmax, MTV, TLG, and COV were significantly associated with distant metastasis (all P<0.05), except COV at SUV 1.0 (P=0.65). Multivariate regression confirmed COV at an SUV threshold of 2.0 (COV2.0) >0.33 as an independent risk factor [hazard ratio (HR) =3.03, P=0.01]. SII >641.68 was also identified as an independent inflammation-related risk factor (HR =2.84, P=0.003). COV2.0 was positively correlated with SII [odds ratio (OR) =4.55, P=0.03]. The co-high COV2.0/SII status was identified as an independent risk factor for metastasis (HR =5.08, P<0.001). In the independent validation cohort, the metastasis rate in the co-high COV2.0/SII group was 84.20% (16/19), significantly higher than the non-metastasis rate (15.80%, 3/19, P=0.043). The metastasis rate in the co-low COV2.0/SII group was only 17.90% (5/28, P<0.001). No clinicopathological features (age, gender, histological subtype, tumor diameter, smoking history) were associated with metastasis (all P>0.05). Conclusions: F-FDG PET/CT-derived COV2.0 and serum SII may aid in evaluating the risk of distant metastasis in small-size NSCLC, thereby informing more rational treatment and follow-up strategies for lung cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.